Frank Jennings
Oppenheimer Global Opportunities Fund
Under Frank Jennings's guidance, Oppenheimer Global Opportunities Fund has routed the S&P 500 over the past 10 years with a 4% annualized return (vs. --0.5%). But Jennings aspires to bigger gains, and he's willing to take risks to get them. "I am an elephant hunter," he says, "when most [fund managers] are busy poaching rabbits."
One potential elephant: Nektar Therapeutics. Leveraging medicinal polymer chemistry, Nektar's technology is used to modify existing drugs, so they last longer, are less toxic, and generally work better. Partner companies sell nine Nektar-modified drugs, treating cancer, anemia, and immune-system problems, and Nektar has more in the pipeline.
"They may come up with 50 drugs over the next decade," Jennings says, "in which case this stock could go up 10-fold."
--Michael Copeland
NEXT: Royal Gold
